TSXV:RHT.H - Post by User
Comment by
lscfaon Dec 01, 2021 8:56am
166 Views
Post# 34184140
RE:Review of Q1
RE:Review of Q1 Revenue for sept qtr was $1.6 million and a/r increased $1.75 million. Reliq did not collect 1 cent. Reliq is getting played by these clients who had access to US govt. Covid grants.
https://www.ama-assn.org/delivering-care/public-health/summary-paycheck-protection-program-and-health-care-enhancement-act
Gulliver1909 wrote: After reviewing the first quarter numbers in general I am happy as the growth story is ongoing. Should lead to higher prices in the coming months - if the markets keep stable.
Three aspects things I didn´t like:
1) Heavy dilution by 8 million shares. When you review the quarterly results they paid their consultants immediately valid options in the amount of 1-2 million $ per quarter for the last 12 months or so. Hopefully that comes to an end soon. No indication about how they are going to proceed in that aspect. Which consultants get these shares for what kind of service?
2) Following Q4 2021 in her webcast Dr. Crossley guided for 11 million $ revenue in calendar year 2021 - that does not seem to be achievable anymore.
3) Some receivables are longer lasting than 3 months - so I assume the medical customers got paid by medicare/medicaid already. Why didnt they pass over their fee to Reliq? I think originally Dr. Crossley already guided (in the September webcast) that this receivables should have been collected at the end of first quarter (September 30th)?!